The American Cancer Society and the Melanoma Research Alliance selected the first group of scientists to receive newly established research grants to investigate how to reduce side effects resulting from cancer treatments with checkpoint inhibitors.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
